摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,4,5-triamino-6-butoxypyrimidine | 127116-73-8

中文名称
——
中文别名
——
英文名称
2,4,5-triamino-6-butoxypyrimidine
英文别名
6-butoxy-2,4,5-triaminopyrimidine;6-Butoxy-2,4,5-pyrimidinetriamine;6-butoxypyrimidine-2,4,5-triamine
2,4,5-triamino-6-butoxypyrimidine化学式
CAS
127116-73-8
化学式
C8H15N5O
mdl
——
分子量
197.24
InChiKey
YJPPPLCDLDGFGW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    464.0±55.0 °C(Predicted)
  • 密度:
    1.262±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.4
  • 重原子数:
    14
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    113
  • 氢给体数:
    3
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2,4,5-triamino-6-butoxypyrimidine 作用下, 以 为溶剂, 反应 2.0h, 生成 4-Butoxy-7-butylpteridin-2-amine
    参考文献:
    名称:
    Highly Regioselective Alkylation of Pteridine
    摘要:
    Reaction of 2-amino-4-butoxypteridine with a Grignard reagent or an alkyllithium followed by iodine oxidation gives the 7-substituted pteridine, regioselectively.
    DOI:
    10.3987/com-92-s(t)103
  • 作为产物:
    描述:
    6-丁氧基-5-亚硝基嘧啶-2,4-二胺 在 palladium on activated charcoal 氢气 作用下, 以 甲醇 为溶剂, 20.0 ℃ 、100.0 kPa 条件下, 以100%的产率得到2,4,5-triamino-6-butoxypyrimidine
    参考文献:
    名称:
    Novel Regio- and Stereoselective Synthesis of 6-Substituted Pteridines and Naturally Occurring L-erythro-Biopterin
    摘要:
    通过2,4,5-三氨基-6-丁氧基嘧啶与多种2-甲酰氧基环氧乙烷的缩合反应,接着用碘氧化,可以选择性地合成2-氨基-4-丁氧基-6-(1-羟基烷基)蝶啶。从(1S,2S,3S)-2-甲酰基-3-(1-羟基乙基)环氧乙烷合成自然界存在的L-赤型二氢蝶呤。反应过程经过5,6-二氢蝶呤中间体,并通过分子轨道计算讨论了反应机制。
    DOI:
    10.1055/s-1992-26097
点击查看最新优质反应信息

文献信息

  • Novel Regio- and Stereoselective Synthesis of 6-Substituted Pteridines and Naturally Occurring L-<i>erythro</i>-Biopterin
    作者:Shizuaki Murata、Takashi Sugimoto、Shoji Ogiwara、Kouichi Mogi、Hiroaki Wasada
    DOI:10.1055/s-1992-26097
    日期:——
    Condensation of 2,4,5-triamino-6-butoxypyrimidine with various 2-formyloxiranes followed by oxidation with iodine affords 2-amino-4-butoxy-6-(1-hydroxyalkyl)pteridines regioselectively. Naturally occurring L-erythro-biopterin is synthesized from (1S,2S,3S)-2-formyl-3-(1-hydroxyethyl) oxirane. The reaction proceeds via 5,6-dihydropteridine, and the mechanism is discussed with the help of molecular orbital calculations.
    通过2,4,5-三氨基-6-丁氧基嘧啶与多种2-甲酰氧基环氧乙烷的缩合反应,接着用碘氧化,可以选择性地合成2-氨基-4-丁氧基-6-(1-羟基烷基)蝶啶。从(1S,2S,3S)-2-甲酰基-3-(1-羟基乙基)环氧乙烷合成自然界存在的L-赤型二氢蝶呤。反应过程经过5,6-二氢蝶呤中间体,并通过分子轨道计算讨论了反应机制。
  • HAIR DYE AGENT COMPRISING AMINOPYRIMIDINE DERIVATIVES
    申请人:Henkel AG & Co. KGaA
    公开号:US20150209258A1
    公开(公告)日:2015-07-30
    The present application relates to agents for dyeing keratin fibers, in particular human hair, the agent including a cosmetic carrier and at least a compound of formula (I)
    本申请涉及染色角蛋白纤维的药剂,特别是人类头发,该药剂包括化妆品载体和至少一种符合式(I)的化合物。
  • METHODS FOR SYNTHESIZING MOLYBDOPTERIN PRECURSOR Z DERIVATIVES
    申请人:Alexion Pharma International SÀRL
    公开号:EP2675278B1
    公开(公告)日:2016-02-17
  • Methods for Synthesizing Molybdopterin Precursor Z Derivatives
    申请人:Alexion Pharma International Sàrl
    公开号:US20140303367A1
    公开(公告)日:2014-10-09
    Provided herein are synthetic methods for preparing a compound of formula (I): Also provided herein are synthetic methods for preparing a compound of formula (XIII): The disclosure also provides useful intermediates, derivatives, prodrugs, and pharmaceutically acceptable salts, solvates and hydrates of the formula (I) and formula (XIII) compounds. These compounds are useful for treating diseases associated with molybdenum cofactor deficiency.
  • Methods for synthesizing molybdopterin precursor Z derivatives
    申请人:Long Xiangtian
    公开号:US20140323726A1
    公开(公告)日:2014-10-30
    Provided herein are synthetic methods for preparing a compound of formula (I): Also provided herein are synthetic methods for preparing a compound of formula (XIII): The disclosure also provides useful intermediates, derivatives, prodrugs, and pharmaceutically acceptable salts, solvates and hydrates of the formula (I) and formula (XIII) compounds. These compounds are useful for treating diseases associated with molybdenum cofactor deficiency.
查看更多